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Continued improvement of cardiovascular








Background: During the last 35 years the poor ranking of Hungary on the list of life expectancy at birth among
European countries, has not changed. In 1970 our lag behind the leading European countries was the smallest. The
gap was growing between 1970 and 1993 but from 1994 onwards the life expectancy at birth in Hungary has
increased continuously and somewhat faster than in other European countries. The aim of this study was to
analyze the association between decreasing cardiovascular mortality rates, as a main cause of death and the
increase in cardio-metabolic prescriptions and possible changes in lifestyle behavior.
Methods: Analyses were conducted on national data concerning cardiovascular mortality and the number of
cardio-metabolic drug prescription per capita. The association between yearly rates of cardiovascular events and
changes in antihypertensive, antilipidemic and antidiabetic prescription rates was analyzed. The changes in other
cardiovascular risk factors, like lifestyle were also considered.
Results: We observed a remarkable decline of mortality due to stroke and acute myocardial infarction (AMI). The
fall was significantly associated with all prescription rates. The proportion of each treatment type responsible for
suppression of specific mortality rates is different. All treatment types comparably improved stroke mortality, while
antilipidemic therapy improved AMI outcome.
Conclusions: These results emphasize the importance of a comprehensive strategy that maximizes the population
coverage of effective treatments. Hungary appears to be at the beginning of the fourth stage of epidemiologic
transition, i.e. it has entered the stage of delayed chronic noninfectious diseases.
Background
The poor ranking of Hungary on the list of life expec-
tancy at birth in the European Union (EU-25) (22
nd
position in 2005 in the EU-25 countries) has not chan-
ged during the last 35 years but the size of deviation -
expressed in years - from other countries has changed
substantially (Table 1).
In 1970 our lag behind the leading European countries
was the smallest, specifically 5.53 years compared to
Sweden, which was at the top of the list for life expec-
tancy at birth (Table 2).
The gap was growing between 1970 and 1993 i.e. in
1993 the difference was 9.16 years compared to Sweden
and 6.2 years compared to Denmark, which ranked just
one position ahead of Hungary (in 1993 EU-15 coun-
tries) [1]. From 1994 the life expectancy at birth in Hun-
gary has increased continuously and somewhat faster
than in other European countries. More recently (in
2005), the differences to Sweden and Denmark were 7.8
and 5.42 years, respectively.
Figure 1 summarizes the changes of life expectancy at
birth in five Central- and Eastern-European (CEE-5) and
EU-15 countries before and after the post-communist
political transition. Overall, longevity increased by 0.14 -
3.24 years in Central- and Eastern-Europe. After the
transition, life expectancies temporarily decreased in
Central- and Eastern-Europe by 0.3 - 1.0 year but later
improved by 1.61 - 4.66 years. The periods with
decrease and increase in longevity were slightly different
in the countries examined.
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Hungary, cardiovascular diseases are the leading cause
of total mortality, cardiovascular mortality representing
50-60 percent of the total mortality [2]. The new epide-
miological period (1993-2005) is characterized mainly by
a decline in the rate of cardiovascular mortality, which
is responsible for a 55,2% reduction of total mortality in
Hungary [2]. The cardiovascular mortality rate was
640.48/100 000 inhabitants in 1993 and 460.25/100 000
in 2006, respectively, which represents a 28.1% decrease
[3]. On the contrary, mortality caused by malignancies
has not changed substantially. Figure 2 shows the con-
tribution of the main causes of death to the decrease of
m o r t a l i t yr a t ea n dt ot h ei n c r e a s ei nl i f ee x p e c t a n c ya t
birth [2].
The most impressive component of the reduced cardi-
ovascular mortality rate is the decreased number of fatal
acute myocardial infarctions (AMI). In 2007 the mortal-
ity due to AMI dropped to 8400 from 15000 in 1993
[4]. The cardiovascular mortality rate per 100 000 inha-
bitants decreased by 53% during this period. Since 1970
mortality due to stroke has declined by 54.5% and this
is associated with an increase in high blood pressure
therapeutic prescriptions [2]. The improvements in
AMI- and stroke-mortality rates have significantly con-
tributed to the total increase of life expectancy at birth
(0.68 and 0.80 years, respectively).
Despite the recent improvement of life expectancy at
birth in Hungary, the absolute value remains low com-
pared to the international data (the difference was 6.91
years in 2005). This situation might be explained by the
unusually high mortality rates of some important
diseases in Hungary compared to EU-25 countries [1]
(Figure 3).
’Avoidable Mortality’ through health care intervention
is another technique used to quantify the public health
status of a country [5]. In the period 1993-2006 mortal-
ity avoidable by medical management lowered by 43% in
Hungary, and expressed as a proportion of total mortal-
ity, it has been reduced from 22% to 16% [2]. With
regard to medical intervention, approximately half of the
cardiovascular mortality rate fall was attributable to
medical therapies against myocardial infarction, heart
failure and angina pectoris.
In spite of some limitations, the IMPACT model is
primarily used [6] to estimate the number of cardiovas-
cular heart disease (CHD) deaths prevented by each spe-
cific cardiac intervention, or risk factor decline. The
comparison between the increase of cardio-metabolic
prescriptions and cardiovascular mortality rate repre-
sents another approach applied to obtain a more precise
estimate of the role of the reduction of each risk factor.
One of the purposes of our analysis was to examine this
association in the period 2000-2008 in Hungary.
Methods
The Hungarian mortality database (Hungarian Central
Statistics Office, CSO) was the source of data on mortal-
ity and the National Health Insurance Fund provided
the number of prescriptions per capita, both at popula-
tion level. Both databases are freely accessible; no speci-
fic approval was required for use. The yearly data from
2000 until 2008 were used to examine the association
between changes in antihypertensive, antilipidemic and
antidiabetic prescription rates and changes in cardiovas-
cular event rates. Regarding other cardiovascular risk
factors, like lifestyle behavior: diet, smoking, alcohol
consumption, the CSO data on consumption of fat-,
tobacco- and alcohol per capita were used.
Death from Stroke, Acute Myocardial Infarction
Age-adjusted mortality rates from stroke and acute
myocardial infarction among individuals aged >20 years
were considered from the Hungarian Mortality database.
Diagnoses were defined according to the International
Classification of Diseases Ninth and Tenth Revisions
(ICD-9, ICD-10). Mortality rates were standardized to
the age (in groups 25-49, 50-64, 65-79 and 80-years of
age) and gender distributiono ft h eH u n g a r i a np o p u l a -
tion aged ≥20 years in the year 2000. The hemorrhagic
and ischemic stroke data were included. The data source
was the reports of the in-patient care services to the
National Health Insurance Fund about the hospitalized
patients with main diagnosis classified as I60-I62; I63-
I66 according to the ICD.
Table 1 Life expectancy at birth (years) (1970-2005)
1
1970 1980 1990 1993 2000 2005
Austria 70.02 72.78 75.99 76.47 78.66 79.70
Denmark 73.51 74.24 75.11 75.37 77.22 78.44
Finland 70.40 73.73 75.13 76.75 77.78 79.36
France 72.93 74.91 77.62 78.71 79.35 80.49
Hungary 69.30 69.12 69.45 69.17 71.93 73.02
Italy 71.66 74.38 77.20 77.71 79.75 80.30
Spain 72.88 75.60 77.00 77.75 79.49 80.44
Sweden 74.83 75.87 77.77 78.33 79.92 80.82
United Kingdom 71.95 73.71 75.92 76.30 78.06 79.29
Table 2 Difference in life expectancy at birth (1970-2005)
between Hungary and Sweden, Denmark, EU-15
countries respectively (SWE = Sweden, DEN = Denmark)
1
1970 1980 1990 1993 2000 2005
SWE-HUN 5.53 6.75 8.32 9.16 7.99 7.80
DEN-HUN 4.21 5.12 5.66 6.20 5.29 5.42
EU-15-HUN 2,53 5.06 7.03 7.83 6.83 6.91
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Page 2 of 8Figure 2 Contribution of the main causes of death to the decrease of mortality rate and to the increase in life expectancy at birth
between 1993-2000 in Hungary
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Figure 1 Changes in life expectancy at birth in some Central- and Eastern-European and EU-15 countries in the period 1975-2005
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Antidiabetic Therapy
Information about antihypertensive, antilipidemic and
antidiabetic prescriptions was obtained from the National
Health Insurance Fund database compiled yearly from the
dispensing records of all retail pharmacies from the coun-
try. This database does not include information on physi-
cian characteristics, patient-level data (e.g., age, gender,
co-morbidities, or concomitant medications dispensed), or
indications for use. The patient was considered as treated
if the medicine was taken for at least 6 months in the
respective year. We examined the number of prescriptions
dispensed between 2000 and 2008 and normalized the age
to the population of Hungary that was over the age of 20
years in the year 2000. Data were not standardized accord-
ing to gender. Regarding the treatment patterns related to
the ATC groups, no deeper analysis was performed. This
survey had no population wide coverage and data shows a
cross-sectional state, no yearly changes. The number of
Percutaneous Transluminal Coronary Angioplasty (PTCA)
and coronary bypass interventions were examined. The
National Health Insurance Fund data were available for
2004-2007 only.
Statistical Analysis
The relationship between standardized yearly rates of
mortality per 10 000 inhabitants and the numbers of
yearly prescriptions per 10 000 inhabitants was exam-
ined. This analysis was designed to assess the association
between the changes in prescriptions and the changes in
cardiovascular mortality rates as a function of time
(years). In each case, a regression analysis was per-
formed for the standardized mortality rate against pre-
scription rates for hypertension, hyperlipidemia and
diabetes, respectively. We also determined the correla-
tion coefficients between prescriptions and mortality
rates. All of the computations were solved using Med-
Calc statistical software.
Results
In Hungary there were 36.4 and 23.6 fewer deaths/per
1000 deaths from stroke and acute myocardial infarction
i n2 0 0 8t h a ni n2 0 0 0 ,r e s p e c t i v e l y .T h ea g ea n dg e n d e r
standardized annual mortality events improved signifi-
cantly for stroke and myocardial infarction (Figure 4).
Among hospitalized patients, the number of those
with a hemorrhagic stroke decreased by 86% in the per-
iod 2000-2008. The percentage of patients hospitalized
and cured with ischemic stroke almost doubled during
the nine years. The hospital mortality for both types of
stroke decreased continuously over the years: 84% for
hemorrhagic stroke and 55% for ischemic stroke.
Regarding cardiac surgical interventions, the coronary
bypass operations decreased by 75% and the PTCAs
multiplied 1.5 times.
The per capita consumption of different types of
nutrients showed slight changes during 2000-2007. The
fat quantity was the same over the eight years: 145,5 +
3,2 g/day/per capita. According to the COICOP (Classi-
fication of Individual Consumption According to Pur-
pose) the ratio of spending on tobacco increased year by
year, in total with 122.3% from 2000 till 2007; the
spending on alcohol increased from 3.7% to 4.4% [4].
No significant change in consumption of fruits and
vegetables occurred.
Total annual antihypertensive, antidiabetic and antili-
pidemic drug prescriptions increased by 110, 134 and
306% between 2000 and 2008, respectively [7]. The
Figure 3 Ratio of the mortality rate by main cause of death in Hungary compared to EU-25 countries
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Page 4 of 8absolute number of prescriptions in 2008 was the high-
est for antihypertensive drugs followed by antilipidemic
and antidiabetic drugs. The annual growth was signifi-
cant for each prescription (Figure 5).
The declines of mortality by stroke and AMI were sig-
nificantly associated with all prescription rates (Table 3).
The correlation between specific mortality rates and
specific treatments differed. The highest correlations
were observed between stroke mortality and all treat-
ment types and between AMI mortality and antilipi-
demic therapy.
Discussion and Conclusions
In developed countries, cardiovascular diseases are
the leading cause of mortality and hospitalization, and
the major contributors to healthcare costs [8-13]. The
decline of cardiovascular mortality rate is a great success
in many countries, including Hungary. In the introduc-
tion we summarized the continuous improvement in
cardiovascular mortality rate in Hungary.
Often the numbers of CHD deaths prevented or post-
poned by each specific cardiac intervention and by each
risk factor change are calculated using the IMPACT
mortality model [6]. This model includes the number of
CHD deaths, the specific medical and surgical treat-
ments and population-trends in major cardiovascular
risk factors. In the frame of the IMPACT model, the
mortality reduction credited to each treatment is calcu-
lated using the published effectiveness of cardiovascular
treatments and risk factor reductions obtained from
meta-analyses and controlled trials [6,14-16]. Explana-
tions for the mortality decreases remain controversial
[17]. Many authors credit the increasingly widespread
use of effective therapies such as thrombolysis, aspirin,
ACE inhibitors, statins, and coronary artery bypass sur-
gery [18,19]. Others highlight reductions in major cardi-
ovascular risk factors such as high blood cholesterol,
smoking and high blood pressure [17,20].
The majority of authors suggest that risk factor
improvements explain more of the mortality decline
than do treatments. For example, it has been estimated
that the proportion of mortality decline attributable to
risk factor reductions was 57% in the United States
between 1980 and 1990 [21]; 60% in Auckland, New
Zealand, between 1974 and 1981 [22] and 52% between
1982 and 1993 [6]; and 60% in Scotland between 1975
and 1994 [23]. In Finland between 1982 and 1997 CHD
m o r t a l i t yr a t ed e c l i n e db y6 3 %a n dt h ef i n d i n g sh i g h -
light the value of risk factor reduction which explains
52.3-72% of the given improvements [24].
These modeling studies have some caveats: they are
dependent on the variable quality and extent of available
data on cardiovascular risk factor trends and CHD treat-
ment uptakes [25]. All require numerous data inputs
constrained by selection bias and/or make explicit
assumptions. However, this general approach merits
further investigation. It is necessary to develop more
simplified methods to identify the most important
health care activities required to improve mortality and
morbidity rates. This paper describes one such activity:
an increase in special medical prescriptions. Significant
decreases in cardiovascular events initially followed the
introduction and use of antihypertensive drugs in the
1970s [21,26-28]. Despite robust randomized trial evi-
dence confirming the benefits of lowering blood pres-
sure with antihypertensive agents, the expected benefits
of antihypertensive treatment in reducing cardiovascular
events have not been seen in several observational
studies of usual clinical practice [18-20,29]. The first
published statistical study which successfully associates
increased antihypertensive therapy with decreased cardi-
ovascular disease on a national scale, and the improve-
ment in outcomes with the start of a national
hypertension management effort, was published in early
2009 [30]. This study prompted our current analysis,
which takes into account a broader range of cardiovas-
cular treatment modalities.
Figure 4 Decrease in stroke and acute myocardial infarction
age and gender standardized mortality rate between 2000-
2008 in Hungary
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Page 5 of 8Figure 5 The increase of annual prescriptions rate per 10 000 inhabitant for antihypertensive (A), antilipidemic (B) and antidiabetic (C)
drugs between 2000 and 2008 in Hungary
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Page 6 of 8Complex and multiple causes lead to the Hungarian
changes of the last decade presented in this article. Half
of the 4.14 years gained in life expectancy is due to the
decline in cardiovascular mortality. Our findings support
the role of antihypertensive treatment in improving car-
diovascular mortality rates. The antihypertensive pre-
scriptions show the highest absolute number during the
years. However, records show that the antilipidemic
therapies increased most, exceeding the total number of
prescribed therapies for diabetes in 2008. We analyzed
the antilipidemic and antidiabetic prescription rates to
address whether the same association exists for these
classes of drugs. We report here that the extension of
cardiovascular treatment modalities has a beneficial
influence on cardiovascular events. In order to prove
this proposition and to reveal the role of other risk fac-
tors we have to reflect on the changes regarding: life-
style, health care services management, reach of
therapeutic targets.
The increasing awareness of the population towards
healthy behavior is associated with the positive results in
health care statistics, such as decreased mortality, longer
life expectancy. However, healthy behavior is not char-
acteristic of the Hungarian population. According to the
CSO data, presented in the results, tobacco consump-
tion increased, there was no positive change in fat con-
sumption, and a constant fruit and vegetable usage
complete the picture of an unhealthy way of life.
Unfortunately, we could not find data about physical
activity set over time. The data from 2000, 2003 show
that the population over 35 forgets him/herself in the
armchair [4].
The period following 1990 was characterized by large
changes in the health care system, including financing.
In spite of geographical differences, all the modern
medicines, new technologies and interventions were
made available for the population. The institutional
background of the interventional cardiology developed.
We note here, that the data about hospital interventions
and in-patient care could be biased by financial issues,
as the reimbursement is related to the medical care
according to disease related groups (DRG).
The great change in the way of life has not been done,
the hospital interventions are at the very end of the
management of CHD, but the preventive approach in
the field of general practice/family medicine brings the
changes in outcomes. The number of patients under-
going cardio-metabolic treatment increased. Apart from
the number of those under pharmaceutical treatment,
data about the treatment targets of blood pressure and
blood lipids were get from survey performed by Hungar-
ian Society of Hypertension [31]. This survey had no
population wide coverage and data shows a cross-sec-
tional state, no yearly changes. According to the study,
in 2005 39.3% of hypertensive patients under treatment
had blood pressure lower then 140/90 mmHg. This
ratio of the “well treated” (blood pressure under 140/90
Hgmm) group was 44.6%. The education for primary
health care professionals led to better results in the
chronic treatment.
These results emphasize the importance of a compre-
hensive strategy that maximizes the population coverage
of effective treatments and actively promotes a preven-
tion program. There are several limitations to the ana-
lyses that we have conducted. Underlying cardiovascular
risk factors of the Hungarian population are likely to
have increased (obesity, diabetes mellitus), there were
no data on changes in physical activity over time and
the data about the increase on tobacco spending are
soft, includes the price increase too.
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Page 7 of 8There was also a considerable increment in aspirin
use. The role of acute coronary interventions has also
grown - the increase was 49.1% between 2004 and 2007
in Hungary. Health promotion and preventive and cura-
tive medicine have contributed to the improving CHD
epidemiological situation. Hungary appears to be at the
beginning of the fourth stage of epidemiologic transi-
tion, i.e. having left the stage of chronic noninfectious
diseases; it has entered the stage of delayed chronic
noninfectious diseases.
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